Drugs that make it to market have to fund the cost of failure of those that did not make it to the market. As a recent Morgan Stanley report pointed out, the pharmaceutical industry’s current success rates are not sufficient to sustain large internal R&amp;D organizations, making the industry’s current operating model financially non-viable.
已推向市场的药品获得的利润可以抵消一部分未推向市场的药品的研发成本。摩根斯坦利近期发布的一份报告称，制药业现有的药品市场成功率不足以维持大型内部研发机构的发展，这使得该行业现有的运营模式在财政上是不可行的，企业不得不或者提高药品的市场成功率，或者减少药品失败的成本。